Dates & Times
Tuesday, November 3rd at 10:10am-1:45PM ET
Tuesday, December 8th at 10:10am-1:45PM ET

 

Duration
215 minutes

 

Credit Type
CME, CNE, AAPA, AANP

 

Intended Learners

This activity is intended for psychiatrists, nurse practitioners, physician associates, primary care clinicians,  and other healthcare professionals actively diagnosing and treating patients with mental health disorders. 

 

Learning Objectives

After participating in this activity, learners should be better able to: 

• Describe the role of glutamatergic and neuroplasticity-based strategies in informing first-line treatment approaches for MDD  
• Apply current evidence for newly approved and emerging treatments to personalize early-stage management of MDD  
• Evaluate evidence-based augmentation approaches for patients with partial response, including pharmacologic and non-pharmacologic options  
• Implement practical methods to enhance adherence, tolerability, and persistence through real-world strategies and lifestyle integration  
• Use evidence-driven approaches for treatment sequencing and maintenance to achieve remission and sustain long-term functional recovery 
   

 

Continuing Education

In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Note: This statement is not an indication of approved credits. See website for full accreditation information.